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Chapter I    Introduction to Metabolomics 
 
 
Metabolomics and metabonomics encompass the comprehensive 
profiling of multiple metabolite concentrations and their cellular and 
systemic fluctuations in response to drugs, diet, lifestyle, environment, 
stimuli and genetic modulations, in order to characterize the beneficial 
and adverse effects of such interactions. Metabolomics detect and 
quantify metabolites (small molecules <2000 Da) in a biological 
sample. The metabolome is the ensemble of all metabolites contained 
in one cell, tissue, organ or organism. [1] [2] It reflects the current 
biological state (e.g. health or disease) of an organism, because it is 
the endpoint of all interactions and reactions among the genome, 
transcriptome, proteome, microbiome; including also the effects of 
environment, lifestyle, diet, physical exercise and pollutants. 
Metabolomics investigates the final products (metabolites) of the 
biological reactions that take part both at the systemic level, biofluids  
and in specific organs or cell types. In the context of biomedical 
applications, metabolomics will have a preferential role with respect to 
the other "Omics" sciences for its ability to detect in real time the 
response of the organisms to pathological stressors. [3]   
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Fig. 1  The "Omics"  cascade studies [4] 
 
 
Metabolic profiling by NMR 
NMR is widely used in metabolic profiling to identify and quantify 
metabolites, because it  is  a non-destructive  measurement   of  a  
variety  of structurally  different  metabolites.  The quantification is 
based on the peak area of the specific  metabolite,  related  to  the  
peak  area  of  a  known  concentration  of  the  internal standard.  
Moreover, NMR  exhibits  high reproducibility of measurement, and 
requires minimum sample preparation as compared with other 
techniques. The  drawback  of  NMR lies  in  the  low  sensitivity  of  
detection. The  sensitivity  is related to the gyromagnetic ratio (γ) of the 
nuclear spins, experiment acquisition time and the metabolite  
concentrations  that  correspond  to  the  number  of  nuclear  spins  
being  observed.  Metabolite concentrations ranging from µM to mM 
can be readily detected by 1D NMR in ~10 min. Increased signal/noise 
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and spectral resolution can be achieved by the application of a higher 
magnetic field instrument and crioprobe to reduce thermal noise. [5] 
 
NMR experiments for different sample types 
Biofluids such as serum, plasma, urine, amniotic fluid, cerebrospinal 
fluid, saliva and other digestive fluids may be analysed generally using 
high resolution NMR spectroscopy with a 1D 1H NMR experiment. Due 
to the large water signal spectrum, the solvent suppression is required 
during the measurement.  The water suppression can be achieved 
using presaturation, with the application of a weak radio frequency 
(RF). Solvent suppression is required during the measurement due to 
the large water signal dominating the spectrum. Water presaturation by 
applying a weak radiofrequency (RF) during the relaxation/mixing time 
and WATERGATE (WATER suppression by Gradient-Tailored 
Excitation) are the two most frequently used approaches for water 
suppression. [6] [7] For samples containing proteins and lipids, 
phosphate buffer in D2O can be added to the sample and measured by 
a single pulse NMR experiment with water suppression.  For biofluids 
containing macromolecules (serum), T2 relaxation editing by Carr-
Purcell-Meiboom-Gill (CPMG) pulse sequence in NMR experiment is 
utilized to attenuate broad resonances from proteins and lipids which 
have short T2 relaxation time;  deproteinization by organic solvents or 
ultrafiltration can be used.  Non-destructive detection of intact tissues 
and cells can be achieved using solid state magic-angle spinning 
(MAS). [8]   NMR with CPMG and water suppression pulse sequence 
to minimize the spectral line broadening. Standard processes for 
sample preparation are freezing the tissues in liquid nitrogen to quench 
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the enzymatic reactions, followed by grinding the tissue in a cooled 
mortar or with an electric homogenizer, then is packed with the addition 
of D2O, at an angle of 54.7°. [9, 10] 
 
Data preprocessing  
The acquired free induction decay (FID) data can be processed using 
ACD/NMR Processor (ACD/Labs, Toronto, Canada) in which 2x zero-
filling and an exponential window function equivalent to 0.3 Hz line 
broadening is usually applied before Fourier transformation. The 
spectra will be phased, baseline corrected, referenced to standard 
compound signal of a specific chemical shift, and exported as an ASCII 
file.  The ASCII file is imported into Excel and the spectral region from -
0.02 ppm to 10 ppm is chosen for subsequent statistical analysis. 
NMRlab, ProMetab, matNMR and MetaboLab can also be applied to 
process the raw FID data to visualize the spectra. [9, 10] 
   
NMR spectral signal assignment  
1D1H-NMR spectra are routinely acquired due to the high NMR 
sensitivity of the hydrogen nucleus. 1D spectra of samples containing 
complex mixture of  metabolites can be congested due to the 
resonance appeared at the same chemical shift, making the resonance 
assignment a challenge.  2D homonuclear / heteronuclear correlation 
and J-resolved (JRES) experiments can be applied to alleviate the 
congestion of 1D spectrum. Spectral resonance assignment is usually 
performed by searching chemical shift lists, for example, in HMDB, 
BMRB, Chenomx software (Chenomx Inc., Edmonton, Canada), and 
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published literatures along with the analysis of specific J coupling 
patters of the metabolite spin systems. This process is more efficient 
now with the help of MetaboID [11], a graphical user interface that 
offers comparison of experimental spectra with authentic metabolite 
spectra to guide assignment. Resonance assignment is achieved by 
combining the assignment of 1D1H spectra along with the knowledge 
obtained from the 2D experiments of selected samples. [9, 10] 
 
Data processing and statistical analysis  
Normalization is routinely used to account for the dilution effect of each 
sample as well as variation from different batch of measurement [12]. 
Scaling is a variable-based processing approach which is performed on 
the intensity of each metabolite across all samples, and influences the 
result of the multivariate analysis. [13] For instance, principal 
component analysis (PCA) which is performed on mean-centered data 
(e.g. metabolite variable mean is subtracted across all samples) is 
equivalent to performing PCA on a covariance matrix.  Applying PCA 
on standardized variable  requires the data to be scaled with unit 
variance scaling. [14] 
 
Univariate analysis  
To compare each variable in the data containing two groups (for 
example benign and cancer), Student's t-test based on the comparison 
of the two samples is commonly used means. It, however, requires that 
each sample population to have a normal distribution, equal variance of 
the two data populations that are independent leagues. Two sample 
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populations with unequal variances "The Welch"  t test can be applied. 
Analysis of variance one-way (ANOVA) can be applied to test the 
difference between groups, for data that contains more than two 
groups. [14] 
 
Multivariate analysis  
Multivariate analysis can be utilized to account for the impact of all 
metabolites on the outcome of measurement (e.g. cancer and normal).  
Multivariate model can be used to determine the metabolites 
contributing to the result as well as predicting the result.  [14] [15] [16] 
 
Unsupervised analysis  
Unsupervised analysis is the application of statistical models without 
the prior knowledge of the sample classification labels and it is usually 
the first step in data pattern exploration.  PCA is representative of the 
unsupervised method to examine the structure of the data set.  Scores 
plot is generated to assess the clustering of different samples, with the 
corresponding loadings plot demonstrating the variables accounting for 
the most. In addition, the cluster analysis, which is useful for the 
visualization of subgroups of multivariate is also used in metabolomics 
data analysis. [15] [16] 
 
Supervised analysis  
In supervised analysis, information of sample class labels (e.g. disease 
and control) are also utilized in building the statistic models.  
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One commonly used analysis is PLS-DA which maximizes the 
covariance between predictor variables and the response variables 
(classes of each sample) [17].  It uses variable importance to projection 
(VIP) scores to demonstrate the contribution of each variable to the 
model, with metabolites VIP scores> 1 considered important in 
classification.  If class separation is not observed in scores plot of PLS-
DA model, orthogonal partial least squares discriminant analysis 
(OPLS-DA) can be performed [18].  It presents similar prediction ability 
to PLS-DA. Diagnostic parameters such as the number of 
misclassifications, cross-validated explained variation Q2 and the Area 
Under the Curve (AUC) of a Receiver Operating Characteristic (ROC) 
analysis are commonly used to indicate the model performance. [19] 
 
Model validation  
To assess the predictive ability of the multivariate models, cross 
validation (CV), permutation or bootstrap can be conducted.  Cross 
validation involves separating the data into a training set (e.g. PLS-DA), 
and the resulting model is used to predict the classes of the test set.    
A permutation test can assess whether the classification based on true 
sample class is significantly better than classification based on 
randomly assigned sample class.  In bootstrap method It's generates a 
new data set the same size as the original by sampling with 
replacement from the original data set, used to build the prediction 
model, and the validation is applied on the original data set. [20]    
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Pathway analysis in disease biomarker discovery  
Metabolic pathway analysis is essential for the understanding of 
cellular processes of specific diseases. After the identification of 
potential metabolite biomarkers, the particular pathway can be 
assessed using databases such as KEGG [21] and HMDB [22], or 
searching in literatures pathway that contain metabolite and disease.    
The enzymes controlling the metabolite levels in the cell: impact on the 
biomarker level and promote understanding of mechanisms associated 
with the specific disease. 
 
PhD program 
The research activity of this PhD program included the application of 
the NMR technique for the metabolomics analysis, of bio-fluids deriving 
from populations of patients respectively affected by salivary gland 
tumor, antiphospholipid autoimmune syndrome and altered lipid profile. 
This NMR metabolomic screening was aimed  i) at the definition of a 
metabolomic  profile that may be patognomonic of the disease under 
scrutiny and  ii) at the identification of biomarkers to be used with 
diagnostic and prognostic scope. 
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Biofluids and investigated diseases 
Saliva 
Saliva is an important physiological fluid that contains a highly complex 
mixture of substances, it is easily accessible and contains analytes 
that, like those present in serum or urine, are sensitive to the overall 
health status. The Human Saliva Metabolome Database 
www.salivametabolome.ca)  report 1235 possible metabolites in saliva 
(735 detected and quantified by various techniques). Of these, due to 
the NMR sensitivity, almost 20 can be detected by NMR spectroscopy. 
For these reasons, in the future saliva could play a role in the definition 
of diseases. [23] More interestingly, a recent paper demonstrated that a 
clear individual metabolic phenotype exists in saliva, although it is 
slightly less individual-specific than the urinary phenotype, probably 
because stronger underlying homeostatic processes occur in saliva. 
[24]  During my PhD program I performed a NMR-based metabolomic 
study of  saliva of patients suffering of salivary gland tumors.  
 
Serum 
Among the most common biological specimens analysed in 
metabolomics there is blood serum (or plasma). It is collected with low 
invasiveness, and is rich in biological information. Blood is the main 
carrier of small molecules in the body, and it contains all the molecules 
that are secreted by different tissues in response to different 
physiological needs or stresses [25]. The Human Serum Metabolome 
Database, (www.serummetabolome.ca), contains information on about 
4500 metabolites, of them 1986 detected and quantified by various 
techniques. It is very important that metabolomic samples are collected 
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following rigorous standard operating procedures (SOPs), for the 
experimental reproducibility and data exchange. [26] [27]  During my  
PhD program I performed a NMR-based metabolomic study of blood 
sera of patients suffering of antiphospholipid syndrome; 
hypercholesterolemy;  amyotrophic lateral sclerosis.  
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Chapter II   Metabolomic signature of salivary gland tumors 
 
Abstract 
In the present work, we present a NMR-based metabolomic study of 
saliva of patients suffering of salivary gland tumors. Our data show that 
individuals suffering parotid tumor have a characteristic metabolomic 
profile with abnormalities associated to the metabolism of acetate, 
alanine, lactate, methanol, phenylalanine, propionate, succinate. We 
have identified for the first time the metabolomic fingerprint 
characterizing parotid tumor patients disease having potential 
application to improve timely diagnosis and appropriate therapeutic 
approaches.  
 
Introduction 
Human saliva is secreted from three pairs of major salivary glands, 
namely, parotid gland, submandibular gland, and sublingual gland lying 
at the vicinity of oral cavity, and numerous minor salivary glands lying 
beneath the oral mucosa. [1] Cancers affecting the salivary glands 
have been an increasing incidence.  Etiologic factors are not clear, they 
can occur at any age, but are more common in people over 50, 
including impact of gender differences. [2] Nutrition may be a risk 
factor, as well as irradiation or a long-standing histologically benign 
tumor that occurs at youth. Adenoid cystic, mucoepidermoid low-grade, 
acinic cell carcinomas are malignant  tumors showing widely different 
patterns of growth, with a prognosis correlating mainly with histological 
subtype. [3] Pleomorphic adenoma and Warthin’s tumor, are the most 
recurrent benign parotid tumors, that may be subjected to malignant 
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transformation. [3] Warthin's tumors are commonly asymptomatic, 
affect predominantly men in the 5th and 6th are typical of smokers, in 
contrast to other salivary gland tumors. [4] Physical examination is the 
most important tool for diagnosis, and histology allows for the 
differentiation between malignant tumor and other benign conditions.  
At present, salivary gland cancer is not detected until it reaches an 
advanced stage, which would generally result in a poor prognosis and 
survival rate. Therefore, early detection as well as the screening of high 
risk populations with precancerous lesions remains to be an unmet 
need. [3] [5] Metabolomics is the large-scale study of metabolites, 
within cells, biofluids, tissues or organisms. These directly reflect the 
biochemical activity and state of cells. In NMR based metabolomic 
analysis a variety of compounds (charged, neutral, hydrophobic, 
hydrophilic), are simultaneously qualitatively and quantitatively 
detected in biologic samples, [6] providing a significant contribution to 
the understanding of the biochemical pathways involved in many 
unsolved diseases.[7] Saliva is an attractive diagnostic fluid because it 
has several key advantages for disease diagnosis and prognosis. For 
example, low invasiveness, minimum cost, and easy sample collection 
and processing. Saliva contains a large array of metabolites, many of 
which can be informative for the detection of diseases. [8]  
Metabolomic examination of saliva from patients suffering of salivary 
gland tumor is expected to be high informative of the tumor 
etiopatogenesis given that saliva represents the bio-fluid surrounding 
the tumor. Therefore, in these cases, the conventional oral 
examination, coupled with the integration of the salivary metabolite 
signatures, may become an applicable strategy for early detection of 
oral precancerous lesions and cancer. [9] In the present work, using 1H 
NMR spectroscopy, we analyze the saliva metabolomic profile of 
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subjects affected by parotid tumor.  These data evidence the existence 
of several metabolites distinctive of pathological state. Salivary gland 
tumor, as many other cancers, is a complex disease, resulting from an 
interdependent series of biochemical alterations, rather than a single 
disruptive event. In this case our approach aimed at the identification of 
a panel of metabolite markers rather than a single biomarker, will 
improve the sensitivity and specificity for detection. Integrating the 
protocols of tumor grading and histological classification. This 
procedure will enhance the management of the disease in the respect 
of the precision medicine and a gender oriented medicinal 
approach.[10] 
 
Methods 
Participants   
One hundred (100) participants were selected from Department of 
Otolaryngology, DEA III Liv. Nocera-Pagani, Salerno from July 2014 to 
July 2016. 50 participants (male/female: 30/20) had been previously 
diagnosed for suspected parotid tumor according to the revised 
diagnostic protocols, [3] whereas the control group, (50 subjects, 
male/female: 30/20) comprised healthy volunteers without major 
illnesses. Inclusion criteria consisted of all salivary gland tumors (SGT) 
patients and healthy individual who had voluntarily agreed to participate 
in this study, while exclusion criteria included subjects presenting any 
medical conditions or with a recent history of drug addiction or alcohol 
abuse.  
 
 - 20 - 
Sample collection and preparation  
Saliva samples were collected from male and female according to the 
standard operating procedure (SOP) for metabolomic-grade saliva 
samples recently defined. [11] Saliva was collected and stored into 
Sartstedt Salivette®  hygienic saliva collection devices at - 80 °C in 
Greiner cryogenic vials. Before being transferred to a 5 mm heavy-
walled NMR-tube, samples were thawed at room temperature and 
thereafter spin at 3000 rpm using Vivaspin® 6 centrifugal concentrator, 
to remove proteic and particulate matter. The saliva supernatant was 
removed. To prepare NMR sample, 425 µL of each saliva sample were 
added to 25 µL of 1M potassium phosphate buffer (pH 7.4) and 10 µL 
D2O. Trimethylsilyl propionic-2,2,3,3-d4 acid, sodium salt (TSP 0.1% in 
D2O) was used as an internal reference for alignment and 
quantiﬁcation of the NMR signals. [11] 
 
NMR spectroscopy and processing 
NMR experiments were carried out on a Bruker DRX600 spectrometer, 
equipped with a 5 mm triple-resonance z-gradient CryoProbe. 
TOPSPIN, version 2.1 or 3.0, was used for spectrometer control and 
data processing (Bruker Biospin). 1D NOESY experiments were 
acquired using spectral with of 14 ppm, 16k data points, excitation 
sculpting for water suppression, 192 transients, 4s relaxation delay and 
60ms mixing time. The pulse sequence used included an excitation 
sculpting routine for the suppression of the water signal. [12] Due to the 
effect of excitation sculpting on the signal height of resonances in the 
region close to the water resonance, [13, 14] the metabolites that have 
resonances close to this region (ascorbate, glucose, mannose and 
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pyroglutamate) were quantified using resonances from those 
metabolites in other spectral regions. A weighted Fourier transform was 
applied to the time domain data with a 0.5 Hz line-broadening followed 
by manual phase and baseline correction in preparation for targeted 
profiling analysis. 
 
Data Analysis 
NMR spectra were manually phased and baseline corrected. 
Quantification of salivary metabolites was achieved using Chenomx 
NMR-Suite v8.0 (Chenomx Inc.). Briefly, the Chenomx profiler is linked 
to a database containing more than 250 metabolite NMR spectral 
signatures encoded at different spectrometer 1H frequencies, including 
600 MHz (http://www.hmdb.ca). Comparison of the spectral data 
obtained for each saliva sample with the Chenomx metabolite library 
results in a list of compounds together with their respective 
concentrations based on the known concentration of the added internal 
reference compound, TSP.  Each spectrum was analyzed three times.  
 
 
Multivariate Data Analysis 
Multivariate data analysis based on projection methods was applied for 
statistical data analysis. Specifically, exploratory data analysis was 
performed by principal component analysis (PCA) while a projection to 
latent structures (PLS-DA)-based method was applied to discriminate 
the samples. While PCA is a well-known technique used in multivariate 
data analysis, the PLS-based approach is a robust regression 
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technique used to investigate the relationships existing between two 
blocks of data, usually called X- and Y-block and has predictive 
applications. In the present study, discriminant classification was 
carried out using partial least squares-discriminant analysis, a method 
based on the PLS regression algorithm. Projection methods in 
multivariate data analysis were performed by using SIMCA-P+ software 
(Version 12.0, Umetrics, Umea, Sweden). The entire data matrix, after 
log transform and Unit Variance scaling, was first analyzed by PCA to 
define homogeneous cluster of samples (Exploratory data analysis). 
Following PCA, classification of samples was accomplished through 
the use of discriminant chemometric classification technique. The aim 
of classification is to assign a sample to two (or more) categories based 
on the measured variables [15]. With these basis, discriminant 
classification techniques divide the hyper-space demarcated by the 
variables in a number of regions, as the number of classes to be 
considered, so that if an unknown sample falls in a particular region it is 
assigned univocally to the corresponding class. [16] In the present 
study, discriminant classification was carried out using partial least 
squares-discriminant analysis, a method based on the PLS regression 
algorithm. In order to use a regression algorithm for classification, the 
information about the presence of the pathological condition has to be 
coded in a binary vector, which takes the value 1 for one class 
(pathological) and -1 for the other (healthy). A PLS model is then built 
between the experimental matrix X and the coded y (the class), and 
classification is accomplished on the basis of the predicted response y, 
which can assume any real value (supervised method). Models were 
validated by cross-validation techniques and permutation tests 
according to standardized good practice to minimize false discoveries 
and to obtain robust statistical models. A small number of metabolites 
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changing during the experiment was extracted and the behavior of 
each single metabolite was studied by linear mixed-effects model for 
longitudinal studies. All the different pretreatments provided good 
discriminant ability in calibration and cross-validation (above 90%). [15] 
[16] We submitted our data to MetaboLights database with ID code: 
MTBLS421. 
 
 
Results 
 
Metabolomic ‘snapshot’     
For each sample, 17 metabolites were identified and quantified. 
To identify the metabolomic ‘snapshot’ in salivary gland tumors 
patients, 1H-NMR data were processed according to multivariate data 
analysis (MVA) by using both unsupervised and supervised projection 
methods.  
The dataset was log-transformed, unit variance centered and scaled. 
Normalized data were analyzed by defining a matrix composed of 100 
observations and 17 variables. The data collected were then 
investigated using PCA. 
The first component explained the 44% of variance while the second 
the 10%. The choice of principal components was done considering the 
fitting (R2X) and predictive values (Q2X), for the PCA model, in our 
case the second component gave the closest values to 1 for both of 
them. 
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Figure 1 shows the PCA score scatter plot for the 1H-NMR spectra of 
the salivary gland tumors. Four observations fell outside the confidence 
ellipse. Visual inspection evidences separation into two groups almost 
corresponding to patients versus healthy donors. Some data were 
scattered widely on the left side of the graph with slight overlap 
between the two groups. The fitting (R2Y) and predictive (Q2Y) values 
for the PLS-DA model were respectively 59% and 23%. Visualization of 
metabolites using loading scatter plot PLS-DA was carried out to 
identify potential metabolites that are responsible for the discrimination 
showed in PLS-DA score scatter plot. Loading scatter plot showed 
potentially significant metabolites based on contributions and reliability 
to the separation observed in score scatter plot. Metabolites in the 
loading plot that were distant away from the origin and close to the 
vertical axis (separation based on the first principal component) could 
be considered responsible for the exhibited separation in PLS-DA 
score scatter plot (Figure 2A). Inspection of loading scatter plot (Figure 
2B) points to acetate, alanine, lactate, methanol, phenylalanine, 
propionate, succinate as metabolites distinctive of gland tumor 
pathological saliva. 
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Fig. 1  PCA score scatter plot for the 1H NMR data collected in 1H NMR spectra of human SGT 
saliva using 17 measured metabolites from 50 SGT patients and 50 donors. Red and green 
triangles correspond to data SGT patients and healthy donors respectively. 
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Fig. 2  PLS-DA score scatter plot (A) and PLS loading scatter plot (B) for the 1H NMR data 
collected in 1D NOESY spectra of human SGT saliva using 17 measured metabolites 
from 50 SGT patients and 50 donors. In Fig. 2A Red and green triangles correspond 
to data SGT patients and healthy donors respectively. 
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scatter PLS score plot (Fig. 3) reported two groups having limited 
central region overlap; in particular, circled regions correspond to 
pleomorphic adenoma (ap) and warthin tumor (tw) histological 
subtypes. 
 
 
 
Fig. 3  PLS-DA score scatter plot for the 1H NMR data collected in 1H NMR spectra of human 
SGT saliva using 17 measured metabolites from 50 SGT patients and 50 donors. Red triangles 
correspond to data of SGT patients and green triangles to data of healthy donors. Circled 
regions correspond to pleomorphic adenoma (ap) and Warthin tumor (tw) histological subtypes. 
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Gender Differences in total metabolomic profile 
To establish metabolomic profile specificities correlated with gender in 
salivary gland tumor diseases, we performed statistical analysis on the 
subset of 1H-NMR data separately collected on female and male 
salivary gland tumors. Two separate data matrices were generated: the 
first included 17 metabolites for 30 males and the second 17 
metabolites for 20 females. The data of each matrix were 
independently aligned, pre-treated and analyzed using PCA and PLS-
DA. In the case of the males the first component explains 36% of 
variance while the second the 0,8%. In the case of the females the first 
component explains 61% of variance while the second the 14%. The 
choice of principal components was done on the basis of for the PCA 
model. To improve the separation observed with the PCA model, 
supervised PLS-DA was applied fitting (R2Y) value resulted 53% in and 
predictive (Q2Y) value resulted 28%, in the case of males, and  fitting 
(R2Y) value resulted 63% in and predictive (Q2Y) value resulted 28%, 
in the case of females. Even in this case PLS-DA was performed using 
discriminant analysis as a classifier (Y block). The information about 
the presence of the pathological condition has to be coded in a binary 
vector, which takes the value 1 for one class (pathological) and -1 for 
the other (healthy).  PLS-DA (Figure 4A, 4B) statistical analysis 
confirmed, even for this data set, the metabolites distinguishing 
pathological and donors saliva. In particular abnormal presence of 
alanine, glycine, lactate, methanol proved to be characteristic of 
salivary gland tumors male pathological state. 
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Fig. 4  PLS-DA score scatter plot (A) and loading scatter plot (B) for the 1H NMR data collected 
in 1D NOESY spectra of human male SGT saliva using 17 measured metabolites from 30 male 
SGT patients and 30 male donors. In Fig. 4A red triangles correspond to data of male SGT 
patients and green triangles to data of male healthy donors. 
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Fig. 5  PLS-DA score scatter plot (A) and loading scatter plot (B) for the 1H NMR data collected 
in 1D NOESY spectra of human female SGT saliva using 17 measured metabolites from 20 
female APS patients and 20 female donors. In Fig. 5A red triangles correspond to data of 
female SGT patients and green triangles to data of female healthy donors. 
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Abnormal presence of amino acid alanine, glucose, lactate, 
phenylalanine (f) , pyruvate,  proved to be characteristic of salivary 
gland tumor in female saliva pathological state (Figure 5A, 5B). 
 
Discussion  
Cancers affecting the salivary glands have been an increasing 
incidence especially in male over fifty-age population. At moment, this 
cancer is diagnosed using physical and histological examination, being 
almost undetectable until it reaches an advanced stage, which may 
result in a poor prognosis and survival rate. Early diagnosis as well as 
the screening of high-risk populations with precancerous lesions is 
considered an unmet health need.  
In the reported work, we performed a NMR based metabolomics 
analysis of saliva from subjects affected by parotid tumor. We analyzed 
saliva of 50 patients and 50 healthy donors respectively classified in 30 
males and 20 females. PCA statistical analysis, of 1H NMR data 
collected in 1D NOESY spectra (Figure 1) evidenced that the 
metabolomic profiles of saliva including male and female samples do 
not permit a significant discrimination between SGT patients and 
healthy donors. In this case, we observe only weak evidences of 
metabolites potentially distinctive of saliva gland tumor; in particular 
acetate, alanine, lactate, methanol, phenylalanine, propionate, 
succinate. Among these, propionic acid, methanol, and acetate occur 
ubiquitously in the gastro-intestinal tract of humans and other 
mammals, as an end-product of the microbial digestion of 
carbohydrates. [17] 
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Gender differences are of interest from a variety of perspectives and 
have been the focus of a number of studies for many years. The impact 
of gender differences in the prevalence, manifestation and 
management of cancer diseases have been widely studied. [2] As 
previously reported, epidemiological data show that SGT tumor have 
prevalence in male, [18] considering such differences, it is in general 
possible to improve the understanding of the epidemiology and the 
clinical outcome of the diseases. On this basis, we repeated our 
statistical analysis, considering subsets of data classified according to 
gender. PCA statistical analysis for 30 human male SGT saliva and 30 
male healthy donors evidences a more significant separation of 
metabolomics profiles (Figure 3).  In particular PLS-DA loading scatter 
plot shows that alanine, glycine, lactate are metabolite distinctive of the 
pathological state in males. On the contrary considering the female 
subset of samples, the separation of pathological and healthy 
metabolomics profiles appears uncertain. In this case we observe weak 
evidence that alanine, glucose, lactate, phenylalanine, pyruvate, are 
distinctive of the pathological state.  
An outlook to the metabolites distinguishing healthy donors from 
patients shows that lactate and alanine appear always distinctive of the 
pathological state in each set or subset of samples.   Therefore, for 
these metabolites we studied the correlation with abnormalities in the 
biochemical pathways using human metabolome database. This 
analysis, shows that in distinct tumor types, metabolic profiles vary with 
respect to metabolites, such as alanine, glycine, lactate. [19] 
Concerning lactate, it is known from scientific literature that the so 
called Warburg effect, consisting in increased glucose uptake and 
accumulation of lactate, is a common feature of cancer cells.  In this 
case, cancer cells produce pyruvate from a high rate of glycolysis, and 
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subsequently transform pyruvate in lactic acid by fermentation in the 
cytosol. The Warburg Effect is thought to be the result of mutations to 
oncogenes and tumour suppressor genes, [20] [21] [22] moreover 
accumulation of lactate contributes to the immune escape in solid 
tumors and is a pivotal and early event in the development of 
malignancies. [23]  [24] [25] [26] 
Alanine is a nonessential amino acid made in the body from the 
conversion of the carbohydrate pyruvate. It is an important regulator in 
glucose metabolism. Altered levels of alanine and phenylalanine were 
found in surrounding biofluids of several cancers such as breast, 
pancreatic and oral cancer .[27]  
 
Conclusions 
Our NMR-based metabolomic study revealed different metabolomic 
profiles in saliva of male patients affected by salivary gland tumors 
compared with the profiles of age, gender, and sampling-date matched 
control individuals. Our approach provide preliminary data for the 
identification of metabolites that can be used as metabolomics 
fingerprint of salivary gland tumor. Determination of metabolomics 
fingerprint, rather than single metabolic biomarker, may fully reflect the 
multifactorial nature of oncogenesis and the heterogeneity of oncogenic 
pathways, providing precious elements to integrate diagnostic 
laboratory and clinical tests. [18] 
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Chapter III  Metabolomic signature of antiphospholipid syndrome 
 
Abstract 
Antiphospholipid syndrome (APS) is a rheumatic inflammatory chronic 
autoimmune disease inducing hypercoagulable state associated with 
vascular thrombosis and pregnancy loss in women. Cardiac, cerebral 
and vascular strokes in these patients are responsible for reduction in 
life expectancy. Timely diagnosis and accurate monitoring of disease is 
decisive to improve the accuracy of therapy. In the present work, we 
present a NMR-based metabolomic study of blood sera of APS 
patients. Our data show that individuals suffering APS have a 
characteristic metabolomic profile with abnormalities associated to the 
metabolism of methyl group donors, ketone bodies and amino acids. 
We have identified for the first time the metabolomic fingerprint 
characterizing APS disease having potential application to improve 
APS timely diagnosis and appropriate therapeutic approaches.  
 
Introduction 
 
Antiphospholipid (aPL) syndrome (APS) is a rheumatic inflammatory 
chronic autoimmune disease characterized by the presence of auto-
antibodies circulating in the blood directed against phospholipids 
(aPLa). [1] The autoimmune reaction induces inflammatory processes 
on the vessel walls, so that APS patients suffer for a hypercoagulable 
state associated with vascular thrombosis and pregnancy loss in 
women. [2] APS is diagnosed based on clinical symptoms of venous or 
arterial thrombosis, pregnancy morbidity and on laboratory tests 
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consisting in the detection of lupus anticoagulant (LA) and other 
autoantibodies directed against cardiolipin (aCL) and β2-glycoprotein I 
(aβ2GPI). The correlation between the positivity to one or more of 
these markers and the prognosis of the disease is unclear. Specifically 
the association with thrombosis is strong with full positive aPL profile 
(triple positivity), but the risk is uncertain when one or two differently 
combined test are positive. [3, 4]  Cardiac, cerebral and vascular 
strokes in these patients are responsible for a significant reduction in 
life expectancy [5] and indeed, the cardiac disease course in APS 
patients may rapidly progress from asymptomatic to severe life-
threatening manifestations difficult to deal with. Timely diagnosis and 
accurate monitoring of APS course is essential to improve accuracy of 
therapy, avoiding approaches based on medical empiric protocols. 
APS, as many other autoimmune diseases, is characterized by a 
heterogeneous nature that has a dramatic impact on the diagnosis and 
the treatment of the disease. Moreover APS is a gender specific 
pathology with a prevalent incidence in women and gender specificities 
with regard to the clinical and laboratory diagnostic profiles. In recent 
years, metabolomic studies have provided a significant contribution to 
identify the biochemical pathways involved in many unsolved diseases 
as well as great support for the appropriate diagnosis, monitoring and 
therapeutic approach of these diseases. [6] Nuclear magnetic 
resonance (NMR) spectroscopy is a robust and reliable technique for 
metabolomic applications: a variety of compounds (charged, neutral, 
hydrophobic, hydrophilic) can be simultaneously qualitatively and 
quantitative detected using several different types of biologic samples, 
such as isolated cells, tissues or body fluids. [7] In the present work, 
using proton nuclear magnetic resonance (1H-NMR) spectroscopy, we 
analyzed the blood sera metabolomic profile of APS patients. Our data 
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define the first metabolomic dataset useful for an early APS diagnosis 
and a correct monitoring of disease. The first stratification of APS 
patients according to the gender offers preliminary indications for the 
management of the disease according to the gender oriented medicinal 
approach. [8] 
 
Methods 
Participants   
Fifty-four (54) participants were selected from Clinical Pathology 
Laboratory of DEA III Liv. Nocera-Pagani, ASL Salerno from July 2014 
to March 2015. One-half of the present patients (27/54; 50%, 
male/female: 10/17) had been previously diagnosed according to the 
revised diagnostic protocols, [9] whereas the control group comprised 
healthy volunteers without major illnesses (27 subjects, male/female: 
10/17). Inclusion criteria consisted of all APS patients and healthy 
individual who had voluntarily agreed to participate in this study, while 
exclusion criteria included persons who already had, or recently had, 
any medical conditions or with a recent history of drug addiction or 
alcohol abuse.  
 
Sample collection and preparation  
Sera samples were collected from male and female according to the 
standard operating procedure (SOP) for metabolomic-grade serum 
samples recently defined. [7] Blood was collected into standard blood 
collection tubes and allowed to clot at room temperature for 30 to 120 
minutes before centrifugation (1,500 g for 10 minutes at 4 °C). Serum 
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was aliquoted and stored at -80 °C in Greiner cryogenic vials prior to 
NMR spectrometry measurements. Before being transferred to a 5 mm 
heavy-walled NMR-tube, samples were thawed at room temperature 
and thereafter spin at 3000 rpm using Vivaspin® 6 centrifugal 
concentrator to remove proteic and particulate matter. The serum 
supernatant was removed. To prepare NMR sample, 425 µL of each 
sera sample ware added to 25 µL of 1M potassium phosphate buffer 
(pH 7.4) and 50 µL D2O. Trimethylsilyl propionic-2,2,3,3-d4 acid, 
sodium salt (TSP 0.1% in D2O) was used as an internal reference for 
alignment and quantiﬁcation of the NMR signals; the mixture, 
homogenized by vortexing for 30 seconds, was transferred to five 
millimeters NMR tube (Bruker NMR tubes) before the analysis started. 
[7] 
 
NMR spectroscopy and processing 
NMR experiments were carried out on a Bruker DRX600 spectrometer, 
equipped with a 5 mm triple-resonance z-gradient CryoProbe. 
TOPSPIN, version 2.1 or 3.0, was used for spectrometer control and 
data processing (Bruker Biospin). 1D NOESY experiments were 
acquired using spectral with of 14ppm, 16k data points, excitation 
sculpting for water suppression, 192 transients, 4s relaxation delay and 
60ms mixing time. The pulse sequence used included an excitation 
sculpting routine for the suppression of the water signal. [10] Due to the 
effect of excitation sculpting on the signal height of resonances in the 
region close to the water resonance, [11, 12] the metabolites that have 
resonances close to this region (ascorbate, glucose, mannose and 
pyroglutamate) were quantified using resonances from those 
metabolites in other spectral regions. A weighted Fourier transform was 
 - 41 - 
applied to the time domain data with a 0.5 Hz line-broadening followed 
by manual phase and baseline correction in preparation for targeted 
profiling analysis. 
 
Data Analysis 
NMR spectra were manually phased and baseline corrected. 
Quantification of serum metabolites was achieved using Chenomx 
NMR-Suite v8.0 (Chenomx Inc.). Briefly, the Chenomx profiler is linked 
to a database containing more than 250 metabolite NMR spectral 
signatures encoded at different spectrometer 1H frequencies, including 
600 MHz (http://www.hmdb.ca). Comparison of the spectral data 
obtained for each serum sample with the Chenomx metabolite library 
results in a list of compounds together with their respective 
concentrations based on the known concentration of the added internal 
reference compound, TSP.  Each spectrum was analyzed three times. 
 
Multivariate Data Analysis 
Multivariate data analysis based on projection methods was applied for 
statistical data analysis. Specifically, exploratory data analysis was 
performed by principal component analysis (PCA) while a projection to 
latent structures (PLS-DA)-based method was applied to discriminate 
the samples. While PCA is a well-known technique used in multivariate 
data analysis, the PLS-based approach is a robust regression 
technique used to investigate the relationships existing between two 
blocks of data, usually called X- and Y-block and has predictive 
applications. In the present study, discriminant classification was 
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carried out using partial least squares-discriminant analysis (PLS-DA), 
a method based on the PLS regression algorithm. Projection methods 
in multivariate data analysis were performed by using SIMCA-P+ 
software (Version 12.0, Umetrics, Umeå, Sweden). The entire data 
matrix, after log transform and Unit Variance scaling, was first analyzed 
by PCA to define homogeneous cluster of samples (Exploratory data 
analysis). A specific variable, showing significant variation in grouping 
the classes was selected (urea) as Y in partial least squares 
discriminant analysis (PLS-DA). Models were validated by cross-
validation techniques and permutation tests according to standardized 
good practice to minimize false discoveries and to obtain robust 
statistical models. A small number of metabolites changing during the 
experiment was extracted and the behavior of each single metabolite 
was studied by linear mixed-effects model for longitudinal studies. All 
the different pretreatments provided good discriminant ability in 
calibration and cross-validation (above 90%). [13]-[14] We submitted 
our data to MetaboLights database with ID code: MTBLS356.  
 
Results 
The mean concentrations of serum metabolites of APS patient blood 
sera together with a representative 1H-NMR spectrum are reported in 
supplementary material. For each sample, 50 metabolites were 
identified and quantified. Figure 1 reports a graphical representation of 
the mean metabolite concentrations of healthy subjects as reported in 
literature and in our control vs. APS patient blood sera. [15] 
 
 - 43 - 
 
 
Fig. 1   Overview of mean concentrations of serum metabolites as determined by 1H-NMR 
analysis of human blood serum in APS patients, vs. healthy controls in our samples and in 
literature. 
 
Metabolomic ‘snapshot’     
To identify the metabolomic ‘snapshot’ in APS patients 1H-NMR data 
were processed according to multivariate data analysis (MVA) by using 
both unsupervised and supervised projection methods. The dataset 
was log-transformed, unit variance centered and scaled. Normalized 
data were analyzed by defining a matrix composed of 54 observations 
and 50 variables. The data collected were then investigated using PCA. 
The first component explained the 41% of variance while the second 
the 0,4%. The choice of principal components was done considering 
the fitting (R2X) and predictive values (Q2X), for the PCA model, in our 
case the second component gave the closest values to 1 for both of 
them. Figure 2A shows the PCA score scatter plot for the  
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1H-NMR spectra of the APS blood sera. Three observations fell outside 
the confidence ellipse. Visual inspection evidences separation into two 
groups almost corresponding to patients versus healthy donors. Some 
data were scattered widely on the right side of the graph with several 
overlap between the two groups. The visualization of variables plot, 
using loading scatter plot relative to PCA, provides preliminary 
indications on the metabolites responsible for this separation. Urea 
appears as the most influent metabolite (Figure 2B). Based on this 
observation urea was used as variable classifier (Y block) in the 
construction of PLS-DA model (Figure 3A). The fitting (R2Y) and 
predictive (Q2Y) values for the PLS-DA model were respectively 0.744 
and 0.505. Visualization of metabolites using loading scatter plot PLS-
DA was carried out to identify potential metabolites that are responsible 
for the discrimination showed in PLS-DA score scatter plot. Loading 
scatter plot showed potentially significant metabolites based on 
contributions and reliability to the separation observed in score scatter 
plot. Metabolites in the loading plot that were distant away from the 
origin and close to the vertical axis (separation based on the first 
principal component) could be considered responsible for the exhibited 
separation in PLS-DA score scatter plot (Figure 3A). Inspection of 
loading scatter plot (Figure 3B) points to 2-hydroxybutyrate, 
acetoacetate, arginine, betaine, choline, glutamate, glutamine, urea as 
metabolites distinctive of APS pathological sera. 
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Fig. 2   PCA score scatter plot (A) and loading scatter plot (B) for the H-NMR data collected in 
1D NOESY spectra of human APS sera using 50 measured metabolites from 27 APS patients 
and 27 donors. In graph 2A Red triangles correspond to data of APS patients and green 
triangles to data of healthy donors. 
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Fig. 3  PLS-DA Score scatter plot (A) and PLS loading scatter plot  (B) for the H-NMR data 
collected in 1D NOESY spectra of human APS sera using 50 measured metabolites from 27 
APS patients and 27 donors. In Figure 3A red triangles correspond to data of APS patients and 
green triangles to data of healthy donors. 
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Gender Differences in total metabolomic profile 
To establish metabolomic profile specificities correlated with gender in 
APS disease, we performed statistical analysis on the subset of 1H-
NMR data separately collected on female and male APS patient sera. 
Two separate data matrices were generated: the first included 50 
metabolites for 17 females and the second 50 metabolites for 17 
males. The data of each matrix were independently aligned, pre-treated 
and analyzed using PCA and PLS-DA. The first component explains 
46% of variance while the second the 0,78%. The choice of principal 
components was done on the basis of for the PCA model. Even in this 
case PLS-DA was performed using urea variable as a classifier (Y 
block). To improve the separation observed with the PCA model, 
supervised PLS-DA was applied (fitting (R2Y) value resulted 0,520 in 
and predictive (Q2Y) value resulted 0,576. Visualization of metabolites 
using PLS-DA was carried out to confirm metabolites that are 
responsible for the discrimination showed in PLS-DA score scatter plot. 
PCA (Figure 4) and PLS-DA (Figure 5) statistical analysis confirmed, 
even for this data set, the metabolites distinguishing pathological and 
donors sera. In particular abnormal presence of amino acid valine, 
lysine and glycine proved to be characteristic of APS female 
pathological state.  
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Fig. 4  PCA Score scatter plot (A) and PCA loading scatter plot (B) for the 1H-NMR data 
collected in 1D NOESY spectra of human female APS sera using 50 measured metabolites from 
17 female APS patients and 17 female donors. In Figure 4A red triangles correspond to data of 
female APS patients and green triangles to data of female healthy donors. 
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Fig. 5   PLS-DA Score scatter plot (A) and loading scatter plot (B) for the 1H-NMR data 
collected in 1D NOESY spectra of human female APS sera using 50 measured metabolites 
from 17 female APS patients and 17 female donors. In Figure 5A red triangles correspond to 
data of female APS patients and green triangles to data of female healthy donors. 
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Discussion  
APS is a systemic inflammatory autoimmune disease characterized by 
the production of autoantibodies against the blood vessel layers. The 
process targeting the vessel walls increases the risk for vascular 
atherosclerosis ending in cardiac or cerebral stroke. While the correct 
APS diagnosis is not straightforward, as based on the non-trivial 
combination of three laboratory tests and difficult clinical evaluation, 
timely diagnosis is necessary for an appropriate therapeutic decision-
making. Our data provide the first blood sera metabolomic profile of 
APS patient suitable to integrate diagnostic laboratory and clinical 
tests. A metabolic differentiation was evident in individuals affected by 
APS; in particular, we found higher levels of choline, betaine, 2-
hydroxybutyrate, acetoacetate, arginine, glutamate, while lower levels 
of glutamine and valine (Figure 1). It is well known that choline and 
betaine are found in the metabolic pathway of methyl group donors; 2-
hydroxybutyrate and acetoacetate are part of ketone bodies pathways 
of the lipid metabolism, arginine, glutamate, glutamine amino acid 
metabolism. Choline is an essential nutrient that serves as a 
component of phosphatidylcholine (PC), a precursor of the 
neurotransmitter acetylcholine. It can be oxidized to betaine in humans. 
Choline and betaine function as methyl donors in pathways involving 
the re-methylation of homocysteine to methionine to diminish blood 
homocysteine [16] and in DNA and histone methylation, which may 
play potential roles in cardio-metabolic diseases. [17,19] Lack of 
sufficient amounts of choline in the diet can lead to a fatty liver 
condition and general liver damage. This arises from the lack of very 
low density lipoproteins (VLDL), which is necessary to transport fats 
away from the liver. It is worth noting that a metabolomic study of 
metabolic disturbances that underlies systemic lupus erythematosus 
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evidenced alteration in all methyl group donors, including cysteine, 
methionine, and choline, as well as phosphocholines. [20] Betaine 
insufficiency is associated with metabolic syndrome, lipid disorders and 
diabetes, and may have a role in vascular and other diseases. [21, 22] 
Acetoacetate (AcAc) is produced in the liver and serves as alternative 
energy sources for the brain, heart, and skeletal muscle in mammals 
during nutrient deprivation and adherence to low carbohydrate diets. 
[23, 24] It has been correlated with metabolic syndrome and early 
stage type 2 diabetes, abnormal homocysteine levels. [25] Abnormal 
concentrations of acetoacetate (AcAc) is also associated with altered 
immune cell function, highlighting the potentiality of metabolomics 
approach to unveil the biochemical basis of pathological process. 
Arginine, a semiessential amino acid, is taken up by cells using the y+ 
transport system. Its synthesis occurs from citrulline mainly in the liver 
and in the kidney. Arginine is metabolized either in ornithine and urea 
mainly in the liver and the intestine or in citrulline and nitric oxide (NO•) 
in a large number of cell types. Ornithine derived from arginine can be 
metabolized in citrulline (in the context of the urea cycle), in glutamate 
or in polyamines. Arginine dysmetabolism is related to catabolic 
disease such as sepsis, injury and cancer. [26, 27] Immune cells 
exhibit the ability to synthesize both polyamines and NO, which are 
potent immunomodulators. Therefore, evidence from animal and 
human models point to the immunomodulatory role of L-arginine 
metabolism in physiological, as well as pathological conditions. [28] 
Glutamine–glutamate metabolism is an important energetic and 
biosynthetic nutrient for T and B lymphocytes and its irruption has been 
observed in different inflammatory, metabolic, and autoimmune 
pathologies. [29] 
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Gender differences are of interest from a variety of perspectives and 
have been the focus of a number of studies for many years. The impact 
of gender differences in the prevalence, manifestation and 
management of cardiovascular diseases have been widely studied. [8] 
Considering such differences, it is possible to improve the 
understanding of the epidemiology and the clinical outcome of the 
diseases. 1H-NMR data on a subset of sera selected according to the 
gender showed abnormal presence of amino acid valine in female APS 
patients. Valine is one of the three branched-chain amino acids, which 
undergoes oxidation within mitochondria. This data indicate in female 
gender an impact of APS disease on the branched-chain amino acids 
biochemical pathway. [30] Interestingly, 1H-NMR-based serum 
metabolomic studies [31] suggest valine and isoleucine as 
differentiating metabolites for autoimmune rheumatoid arthritis and 
Crohn's disease (CD) diagnosis. These metabolites can be used for 
screening of risky samples at the early stages of autoimmune (CD) 
diagnoses. In particular valine may be a possible candidate marker for 
the diagnosis and the monitoring of APS syndrome in females. 
 
Conclusions 
Our NMR-based metabolomic study revealed significant differences 
among serum metabolic profiles of patients affected by APS compared 
with the profiles of age, gender, and sampling-date matched control 
individuals. These metabolic fingerprints may be used as potential 
serum biomarkers for the selection of timely diagnosis and appropriate 
therapeutic approaches.   
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Chapter IV  Metabolomic profile in hypercholesterolemic sera  
 
Introduction 
 
Human serum includes a large number of components which derive 
from endogenous metabolism and nutritional intake. Serum 
components vary in response to diet. [1] Serum lipid composition is 
probably the most important benchmark in assessing cardiovascular 
risk and disease progression. [2] Serum components, also derived from 
nutritional intake, can affect general metabolism and, more specifically, 
affect molecular mechanisms and pathways linking nutritional intake 
and chronic disease risk.  
To identify the effect exerted by altered lipid composition on the 
genome expression pattern, response of gene expression to serum 
samples from hypercholesterolemic and normocholesterolemic male 
subjects was previously studied. [3] Patients were differentiated on the 
basis of their serum cholesterol levels, assuming nutrition status as 
major cause of observed different effects between the two groups of 
sera. Addition of hypercholesterolemic (average cholesterol 273 mg/dl) 
and normocholesterolemic (average cholesterol 155 mg/dl) sera to 
culture medium of HepG2 human hepatoma cells specifically affected 
gene expression. In this study cells treated with  hypercholesterolemic 
sera showed reduced expression levels of  sterol  regulatory  element  
binding protein 1c (SREBP-1c) mRNA, while UDP-
glucuronosyltransferase 1A1 (UGT1A1) expression was increased, 
when compared to that of cells treated with normocholesterolemic sera.  
[3]  Subsequently, the study was extended, to observe the effect of lipid 
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profile on the whole genome expression pattern by   identifying the 
most relevant mRNAs regulated by nutritional intake, without the 
predetermined selection of specific genes to be observed. As result 
four genes resulted both affected by serum composition: 3-hydroxy-3-
methylglutaryl-CoenzymeA synthase 2 (HMGCS2), glutathione S-
transferase alpha 1 (GSTA1), liver expressed antimicrobial peptide 2 
(LEAP2) and apolipoprotein M (ApoM).  
In the present part of my PhD thesis, using a NMR metabolomics 
approach I studied the metabolomics profile of the aforementioned 
hypercholesterolemic and normocholesterolemic sera to correlate the 
previously identified trascriptomic signature of human hepatoma cells 
to the relative metabolomics profile. 
Only few metabonomic investigations of subjects with a high 
cardiovascular risk profile has been yet reported; however, the 
usefulness of metabonomics in cardiovascular research is strongly 
advocated by some authors.[4] [5]  Nicholson et al. have examined the 
relationship between hypertension, diet, and the metabolome 
alterations. [6] 
 
Methods 
Participants   
Sixteen (16) male participants were selected from the Clinical 
Pathology Laboratory, Santa Maria Goretti Hospital, ASL Latina, Italy.  
All subjects were healthy males aged between 40 and 50 years.  
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Inclusion criteria considered patients presenting abnormal serum 
cholesterol levels and no other disease symptom and healthy individual 
who had voluntarily agreed to participate in this study.  
Exclusion criteria included all subjects presenting any medical 
conditions or additional abnormal serum values, beside those of 
cholesterol. NMR samples preparation and NMR spectra acquisition 
were performed as previously reported. [7]  
 
Sample collection and preparation  
Sera samples were collected from male according to the standard 
operating procedure (SOP) for metabolomic-grade serum samples 
recently defined. [8] Blood was collected into standard blood collection 
tubes and allowed to clot at room temperature for 30 to 120 minutes 
before centrifugation (1,500 g for 10 minutes at 4 °C). Serum was 
aliquoted and stored at -80 °C in Greiner cryogenic vials prior to NMR 
spectrometry measurements. Before being transferred to a 5 mm 
heavy-walled NMR-tube, samples were thawed at room temperature 
and thereafter spin at 3000 rpm using Vivaspin® 6 centrifugal 
concentrator to remove proteic and particulate matter. The serum 
supernatant was removed. To prepare NMR sample, 425 µL of each 
sera sample ware added to 25 µL of 1M potassium phosphate buffer 
(pH 7.4) and 50 µL D2O. Trimethylsilyl propionic-2,2,3,3-d4 acid, 
sodium salt (TSP 0.1% in D2O) was used as an internal reference for 
alignment and quantiﬁcation of the NMR signals; the mixture, 
homogenized by vortexing for 30 seconds, was transferred to five 
millimeters NMR tube (Bruker NMR tubes) before the analysis started. 
[8] 
 - 60 - 
 
NMR spectroscopy and processing 
NMR experiments were carried out on a Bruker DRX600 spectrometer, 
equipped with a 5 mm triple-resonance z-gradient CryoProbe. 
TOPSPIN, version 2.1 or 3.0, was used for spectrometer control and 
data processing (Bruker Biospin). 1D NOESY experiments were 
acquired using spectral with of 14ppm, 16k data points, excitation 
sculpting for water suppression, 192 transients, 4s relaxation delay and 
60ms mixing time. The pulse sequence used included an excitation 
sculpting routine for the suppression of the water signal. [9] Due to the 
effect of excitation sculpting on the signal height of resonances in the 
region close to the water resonance, [10, 11] the metabolites that have 
resonances close to this region (ascorbate, glucose, mannose and 
pyroglutamate) were quantified using resonances from those 
metabolites in other spectral regions. A weighted Fourier transform was 
applied to the time domain data with a 0.5 Hz line-broadening followed 
by manual phase and baseline correction in preparation for targeted 
profiling analysis. 
 
Results 
Data Analysis 
NMR spectra were manually phased and baseline corrected. 
Quantification of serum metabolites was achieved using Chenomx 
NMR-Suite v8.0 (Chenomx Inc.). Briefly, the Chenomx profiler is linked 
to a database containing more than 250 metabolite NMR spectral 
signatures encoded at different spectrometer 1H frequencies, including 
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600 MHz (http://www.hmdb.ca). Comparison of the spectral data 
obtained for each serum sample with the Chenomx metabolite library 
results in a list of compounds together with their respective 
concentrations based on the known concentration of the added internal 
reference compound, TSP.  
 
Multivariate Data Analysis 
Multivariate data analysis based on projection methods was applied for 
statistical data analysis. Specifically, exploratory data analysis was 
performed by principal component analysis (PCA) while a projection to 
latent structures (PLS-DA)-based method was applied to discriminate 
the samples. While PCA is a well-known technique used in multivariate 
data analysis, the PLS-based approach is a robust regression 
technique used to investigate the relationships existing between two 
blocks of data, usually called X- and Y-block and has predictive 
applications. In the present study, discriminant classification was 
carried out using partial least squares-discriminant analysis (PLS-DA), 
a method based on the PLS regression algorithm. Projection methods 
in multivariate data analysis were performed by using SIMCA-P+ 
software (Version 12.0, Umetrics, Umeå, Sweden). The entire data 
matrix, after log transform and Unit Variance scaling, was first analyzed 
by PCA to define homogeneous cluster of samples (Exploratory data 
analysis). Models were validated by cross-validation techniques and 
permutation tests according to standardized good practice, to minimize 
false discoveries and to obtain robust statistical models. In order to use 
a regression algorithm for classification, the information about the 
presence of the pathological condition has to be coded in a binary 
vector, which takes the value 1 for one class (pathological) and -1 for 
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the other (healthy).  A small number of metabolites changing during the 
experiment was extracted and the behavior of each single metabolite 
was studied by linear mixed-effects model for longitudinal studies. All 
the different pretreatments provided good discriminant ability in 
calibration and cross-validation (above 90%). [12]-[13] 
For each sample, 50 metabolites were identified and quantified. Figure 
1 reports a graphical representation of mean concentrations of serum 
metabolites as determined by 1H-NMR analysis of human blood serum 
in HC patients, vs. healthy controls. The figure is related to the 
abnormal metabolites in HC patients. 
  
 
 
 
Fig. 1  Overview of mean concentrations of serum metabolites as determined by 1H-NMR 
analysis of human blood serum in HC patients, vs. healthy controls in our samples and in 
literature 
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Metabolomic ‘snapshot’     
Figure 2 shows PCA score and loading scatter plot for the 1H NMR 
data collected in 1D NOESY spectra of human sera of 
hypercholesterolemic subjects using 50 measured metabolites from 16  
sera of hypercholesterolemic subjects and 16 healthy donors. The data 
set relative to hypercholesterolemic subjects appear well separated 
from those of healthy subjects.  Inspection of PLS-DA score scatter plot 
(Fig. 3A) and loading scatter plot (Fig. 3B) points to 2-hydroxybutyrate, 
acetate, acetone, betaine, cysteine, formate, glutamate, glycine, 
hypoxanthine, isoleucine, lactate, ornithine, as metabolites distinctive of  
hypercholesterolemic sera. The first component explains 21% of 
variance while the second the 14%. The choice of principal 
components was done on the basis of for the PCA model. To improve 
the separation observed with the PCA model, supervised PLS-DA was 
applied fitting (R2Y) value resulted  85.8% in and predictive (Q2Y) 
value resulted 61.2%.  
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Fig. 2  PCA score scatter plot (A) for the 1H NMR data collected in 1D NOESY spectra of 
human sera of hypercholesterolemic subjects using 50 measured metabolites from 16 sera of  
hypercholesterolemic subjects and 16 donors. In graph 2 Red triangles correspond to data of 
sera of hypercholesterolemic subjects and green triangles to data of healthy donors. 
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Fig. 3  PLS-DA Score scatter plot (A) and PLS-DA loading scatter plot (B) for the 1H NMR data 
collected in 1D NOESY spectra of human sera of hypercholesterolemic subjects using 50 
measured metabolites from 16 sera of hypercholesterolemic subjects and 16 donors. In Fig. 3A 
red triangles correspond to data of sera of hypercholesterolemic subjects and green triangles to 
data of healthy donors. 
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Discussion  
Quality and quantity of nutritional intake can affect disease risk and 
serum composition.  It is then possible that diet derived serum 
components directly affect pathogenetic mechanisms.  Previously the 
genes were identified that are selectively regulated in human hepatoma 
cells by treatment with dyslipidemic sera. Accordingly 3-hydroxy-
3methylglutaryl-CoenzymeA synthase expression appeared 
significantly modulated via transcription factors peroxysome 
proliferators activated receptor.[3]  Using an NMR based metabolomics 
approach, our study was aimed to investigate a possible correlation 
between  the trascriptomic signature of hepatoma cell lines, and the 
metabolomics signature of sera. Accordingly, the statistical analysis of 
1H NMR data recorded on 16 hypercholesterolemic vs. 16 healthy 
sera, showed abnormal concentration of hydroxybutyrate, acetate, 
acetone, betaine, cysteine, formate, glutamate, glycine, hypoxanthine, 
isoleucine, lactate, ornithine, as distinctive of  hypercholesterolemic 
sera.  To investigate the implications of these results in term of 
etiopathologic perspective, we compared our results to the data 
deposited in the  HMDB data base. This analysis indicated that among 
the metabolites found in abnormal concentration acetone and 2-
hydroxybutyrate are involved in the biochemical pathway of the keton 
bodies. (Figure 4) These abnormalities evidence a direct relationship 
between the overexpression of HMGCS2 mRNAs [3] involved in the 
expression of enzymes of keton bodies pathway (Figure 4), and the 
products of the same metabolic pathway. Indeed an increased 
expression of HMGCS2 induces increased levels of acetone and 2-
hydroxybutyrate as found in the metabolomic profile of 
hypercholesterolemic sera studied by us. 
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Additionally it is worth of noting that the metabolic abnormalities 
observed in our sample are consistent with the data of previous mNMR 
based metabolomics studies. In particular 2-hydroxybutyrate, ketogenic 
amino acids and glycine [14] were found significantly augmented in 
subjects suffering of atrial ﬁbrillation (AF) when compared to control 
subjects, confirming a pathological role for ketone bodies. [15]  
Finally among the metabolites found in abnormal concentration, 
glutamate, 2-hydroxybutyrate have been previously found associated to 
atherosclerosis and as end product of  damage  of intima artery walls. 
[16] Lactate, 3-hydroxybutyrate, isoleucine and glutamate were found 
at lower concentrations as distinctive of preischemia state in the 
coronary sinus (CS). [17]  
Conclusions 
In the reported study we analyzed the sera of 16 patients affected by 
hypercholesterolemic altered lipid profile, in comparison with an equal 
number of healthy subjects.  Hypercholesterolemic sera previously 
proved to increase in human hepatoma cells, the mRNA expression of 
HMGCS2, an enzyme involved in the pathway of keton bodies. Our 
NMR based metabolomics analysis evidences abnormal concentrations 
of metabolites involved in the keton bodies pathway. This indicates a 
correlation between the trascriptomic profile of hepatoma cells treated 
with hypercholesterolemic sera, and the metabolomics profile of the 
same sera. 
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Fig. 4  Biochemical pathway of the keton bodies 
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